Skye Bioscience, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Deficit and Preferred Stock Subject to Redemption (Detail Textuals)

Stockholders' Deficit and Preferred Stock Subject to Redemption (Detail Textuals) - USD ($)		1 Months Ended										3 Months Ended				6 Months Ended
	May 03, 2017	Mar. 31, 2017	Feb. 28, 2017	Jan. 31, 2017	Dec. 31, 2016	Dec. 29, 2016	Nov. 30, 2016	Oct. 31, 2016	Mar. 31, 2016	Dec. 31, 2015	Aug. 31, 2015	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Aug. 20, 2015
Equity [Line Items]
Number of shares issued for services		605,000
Research and development expense												$ 60,651			$ 459,957	$ 152,751	$ 595,316
Par value of common stock issued (in dollars per share)		$ 0.001			$ 0.001							$ 0.001	$ 0.001	$ 0.001		$ 0.001
Preferred stock, shares authorized												20,000,000				20,000,000
Recognized stock-based compensation expense												$ 181,608				$ 363,216
Series B Preferred Stock
Equity [Line Items]
Number of preferred stock and warrants sold											5,000
Conversion price						$ 0.25		$ 0.40	$ 0.80		$ 0.25	$ 0.25				$ 0.25
Number of shares converted									8	500	13,501,500	250		461		655.625
Number of shares issued in conversion									10,000	625,000		1,000,000		1,152,500		2,622,500
Proceeds from issuance of preferred stock and warrants											$ 5,000,000
Preferred stock, conversion rate										1,250:1		4000:1		2,500:1		4000:1
Liquidation preference value											$ 3,375,000
Aggregate purchase price											$ 1,000
Percentage of conversion amount											115.00%
Value of final judgment rendered against company											$ 100,000
Shares issued, price per share (in dollars per share)																		$ 0.80
Series C preferred stock
Equity [Line Items]
Warrant exercise price (in dollars per share)								$ 0.40
Number of preferred stock and warrants sold								500
Conversion price					$ 0.40	$ 0.25		$ 0.40					$ 0.25
Number of shares converted					39	75		461					386
Number of shares issued in conversion					97,500	300,000		1,152,500					1,544,000
Proceeds from issuance of preferred stock and warrants								$ 500,000
Preferred stock, conversion rate													4000:1
Beneficial conversion feature upon issuance								$ 325,000
Aggregate purchase price								$ 1,000
Number of common stock issued upon conversion of preferred stock								2,500
Liquidation provision common stock equivalent shares								1,250,000
Liquidation provision common stock equivalent value								$ 500,000
Series D preferred stock
Equity [Line Items]
Number of shares called by warrants			125,000	480,000
Warrant exercise price (in dollars per share)			$ 0.41	$ 0.25	$ 0.25									$ 0.25
Term of warrant			10 years
Value of common stock called by warrants			$ 30,000	$ 115,200
Number of preferred stock and warrants sold				1,200
Conversion price				$ 0.25								$ 0.25				$ 0.25
Number of shares converted												506				1,000
Number of shares issued in conversion												2,024,000				4,000,000
Proceeds from issuance of preferred stock and warrants				$ 1,200,000
Preferred stock, conversion rate												4,000:1				4,000:1
Beneficial conversion feature upon issuance				$ 536,000				$ 175,000
Aggregate purchase price				$ 1,000
Number of common stock issued upon conversion of preferred stock				4,000
Liquidation provision common stock equivalent shares				800,000
Liquidation provision common stock equivalent value				$ 200,000
Series E Preferred Stock
Equity [Line Items]
Number of shares sold	$ 0.001
Shares issued, price per share (in dollars per share)	1,000,000
Shares issued, price per share (in dollars per share)	$ 20.00
Gross proceeds received	$ 20,000,000
General and administrative expense
Equity [Line Items]
Recognized stock-based compensation expense												$ 152,171	$ 187,550			$ 304,338
Technology License Agreement
Equity [Line Items]
Number of shares issued for services								100,000
Research and development expense								$ 50,000
Warrants
Equity [Line Items]
Number of shares called by warrants							40,000				6,250,000
Warrant exercise price (in dollars per share)							$ 1.15				$ 1.15
Term of warrant							10 years				5 years
Value of common stock called by warrants							$ 18,400
Warrants \| Series C preferred stock
Equity [Line Items]
Number of shares called by warrants							125,000
Warrant exercise price (in dollars per share)							$ 0.40
Term of warrant							5 years
Value of common stock called by warrants							$ 37,500
Warrants \| Series D preferred stock
Equity [Line Items]
Number of shares called by warrants				480,000
Warrant exercise price (in dollars per share)				$ 0.25
Value of common stock called by warrants				$ 115,200
Common Stock
Equity [Line Items]
Conversion price											$ 0.80
Number of shares converted											1,250